{'fraction_non_alphanumeric': 0.03581267217630854, 'fraction_numerical': 0.012396694214876033, 'mean_word_length': 5.161016949152542, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Genotype, Phenotype, and Virtual Phenotype: Who Needs What and Why?

JIAPAC Vol. 2, No. 4, October/December 2003 Recent guidelines in the clinical management of HIV infection suggest testing for drug resistance is an integral part of antiretroviral therapy (ART). However, tests of antiretroviral (ARV) drug resistance, which measure the susceptibility of a patient’s virus to current ARV medications, come in a variety of flavors, such as genotype, phenotype, and virtual phenotype. Once results are returned, there is a wide array of interpretation systems and algorithms to guide ART. Susceptibility testing provides a way to estimate sensitivity or resistance of HIV-1 to each of the 20 currently licensed ARV medications.